Vical Reports Third Quarter 2010 Financial Results and Updates on Key Programs and Confirms Planned Webcast of Analyst and Investor Day Event
SAN DIEGO, Nov 9, 2010 (GlobeNewswire via COMTEX) -- Vical
Incorporated /quotes/comstock/15*!vicl/quotes/nls/vicl (VICL 2.20, 0.00, 0.00%) today reported financial results for the three months and nine months ended September 30, 2010.
Revenues were $2.3 million for the third quarter of 2010 compared with $3.9 million for the third quarter of 2009, reflecting lower revenues recognized from AnGes MG, Inc., as the company approaches the completion of its Phase 3 Allovectin-7(R) trial. Operating expenses decreased to $9.1 million for the third quarter of 2010 from $11.0 million for the third quarter of 2009, primarily as a result of reduced clinical trial related costs. The net loss was $6.8 million, or $0.12 per share, for the third quarter of 2010, compared with a net loss of $7.0 million, or $0.14 per share, for the third quarter of 2009.
..."
www.marketwatch.com/story/...t-2010-11-09?reflink=MW_news_stmp
SAN DIEGO, Nov 9, 2010 (GlobeNewswire via COMTEX) -- Vical
Incorporated /quotes/comstock/15*!vicl/quotes/nls/vicl (VICL 2.20, 0.00, 0.00%) today reported financial results for the three months and nine months ended September 30, 2010.
Revenues were $2.3 million for the third quarter of 2010 compared with $3.9 million for the third quarter of 2009, reflecting lower revenues recognized from AnGes MG, Inc., as the company approaches the completion of its Phase 3 Allovectin-7(R) trial. Operating expenses decreased to $9.1 million for the third quarter of 2010 from $11.0 million for the third quarter of 2009, primarily as a result of reduced clinical trial related costs. The net loss was $6.8 million, or $0.12 per share, for the third quarter of 2010, compared with a net loss of $7.0 million, or $0.14 per share, for the third quarter of 2009.
..."
www.marketwatch.com/story/...t-2010-11-09?reflink=MW_news_stmp